HREC application submitted; on track to initiate Phase 1 clinical study of GT-02287 this year Acceptance of late breaking abstract for presentation at the International …
BETHESDA, Md., Aug. 07, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (Nasdaq: GANX), a biotechnology company leading the discovery and development of the next generation …
BETHESDA, Md., July 31, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development …
BETHESDA, Md., June 01, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development …
Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical …
BETHESDA, Md., May 03, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX), a biotechnology company leading the discovery and development of allosteric small molecule …
BETHESDA, Md., April 12, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company leading the discovery and development …
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s disease BETHESDA, Md., March 29, 2023 (GLOBE …
Company expects completion of IND-enabling studies of GT-02287 in H1 2023Submission of dossier to start Phase 1 clinical trial of GT-02287 in GBA1 Parkinson’s Disease …
Panel, moderated by Hartaj Singh of Oppenheimer & Co., will be held on Wednesday, March 29, 2023 at 12:00 pm ET BETHESDA, Md., March 22, …
Grant awarded to consortium led by Gain Therapeutics to advance the development of proprietary allosteric small molecule regulators against Alpha-1 Antitrypsin (AAT) Deficiency BETHESDA, Md., …
BETHESDA, Md., March 09, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
Study results support the disease-modifying potential of GCase-targeting small molecule therapy for neuronopathic Gaucher disease BETHESDA, Md., Feb. 27, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, …
Gain to present new preclinical data on its lead programs in GBA1-related diseases BETHESDA, Md., Feb. 02, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: …
BETHESDA, Md., Jan. 12, 2023 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
Presented New Preclinical Data at Recent Medical Meetings Showing Disease-Modifying Potential of Brain Penetrant Small Molecule Parkinson’s Disease Therapeutic, GT-02287 Promoted Matthias Alder to Chief …
Accumulating Preclinical Data Provide Further Support for Disease-Modifying Potential of Brain Penetrant Investigational Small Molecule Therapeutic, GT-02287 Results Presented at the Shaare Zedek Medical Center …
Outgoing CEO Eric Richman will continue to serve as a member of the board of directors and serve as a senior advisor to the Company …
Treatment with GT-02287 Resulted in a Significant Dose-Dependent Improvement of Cellular Lysosomal Health and Fine Motor Skills Results Presented at the International Congress of Parkinson’s …
Presenting Preclinical Data at 2022 International Congress of Parkinson’s Disease and Movement Disorders in Madrid, Spain Upcoming Presentation on GBA-PD program at First International Symposium …
BETHESDA, Md., Sept. 06, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
Presented Additional Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Utility in Parkinson’s Disease and Gaucher Disease …
BETHESDA, Md., Aug. 04, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
BETHESDA, Md., June 02, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
BETHESDA, Md., May 18, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its …
Presented Supportive Preclinical Data for Lead Candidate GT-02287 at Recent Medical Meetings Further Validating Therapeutic Potential and Clinical Study in Parkinson’s Disease and Gaucher’s Disease. …
Lead compound GT-02329 increases GCase levels and activity, depletes toxic substrates glucosylceramide (GlcCer) and glucosylsphingosine (GlcSph) in relevant Gaucher disease (GD) models BETHESDA, Md., May …
Lead Compound GT-02287 is Brain Penetrant, Reduces Alpha-synuclein, and Increases Dopamine in Relevant Neuronal Models BETHESDA, Md., May 06, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, …
BETHESDA, Md., April 26, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming the drug discovery paradigm …
Lead candidate GT-02287 is bioavailable, increases GCase levels, depletes alpha-synuclein, increases lysosomal health, and improves neuronal network and survival in relevant neuronal cell models BETHESDA, …